Back to results
US 2006/0069121 A1Published application
(Arylamidoanilino)nitroethylene compounds
AssigneeOSI Pharmaceuticals, Inc.
InventorsAndrew Crew, An-Hu Li, Bijoy Panicker
Life of this patent
Estimating the term…
Abstract
Compounds represented by Formula (I): or a pharmaceutically acceptable salt or N-oxide thereof, wherein A, Q, Y, R1, R2, and R5 are defined herein, are useful in the treatment of tumors and cancers such as mastocytosis/mast cell leukemia, gastrointestinal stromal tumors (GIST), germ cell tumors, small cell lung carcinoma (SCLC), sinonasal natural killer/T-cell lymphoma, testicular cancer (seminoma), thyroid carcinoma, malignant melanoma, ovarian carcinoma, adenoid cystic carcinoma, acute myelogenous leukemia (AML), breast carcinoma, pediatric T-cell acute lymphoblastic leukemia, neuroblastoma, mast cell leukemia, angiosarcoma, anaplastic large cell lymphoma, endometrial carcinoma, and prostate carcinoma.
Claims18
A compound represented by Formula (I):
- or a pharmaceutically acceptable salt or N-oxide thereof, wherein:
- Q is aryl or heteroaryl, either of which is optionally substituted with 1-4 independent R3 substituents;
- Y is aryl or heteroaryl, either of which is optionally substituted with 1-4 independent R4 substituents;
- Y is aryl or heteroaryl, either of which is optionally substituted with 1-4 independent R4 substituents;
- A is aryl, heteroaryl, cycloC3-10alkyl, heterocyclyl, cycloC3-10alkenyl, or heterocycloalkenyl, each of which is optionally substituted by 1-5 independent R41 substituents;
- R1 and R2 are C0-6alkyl, aryl, heteroaryl, cycloC3-10alkyl, heterocyclyl, cycloC3-10alkenyl, heterocycloalkenyl, C2-6alkenyl, C2-6alkynyl, each of which is optionally substituted by 1-5 independent R42 substituents;
- or R1 and R2, taken together with the N atom to which they are attached, form a heterocyclyl, heterocycloalkenyl, or heteroaryl, each of which is optionally substituted with 1-4 independent R42 substituents;
- R3 is C0-6alkyl, cycloC3-10alkyl, haloalkyl, halogen, cyanoC0-6alkyl, nitroC0-6alkyl, hydroxyC0-6alkyl, C0-6alkylaminoC0-6alkyl, acylC0-6alkyl, substituted acyl, acylaminoC0-6alkyl, substituted acylamino, acyloxyC0-6alkyl, substituted acyloxy, arC0-6alkyl, heteroarylC0-6alkyl, arylhydrazino, alkylsulfonamidoC0-6alkyl, arylsulfonamidoC0-6alkyl, alkylsulfonylC0-6alkyl, arylsulfonylC0-6alkyl, alkylsulfinylC0-6alkyl, heterocyclylsulfonylC0-6alkyl, silyl, siloxyC0-6alkyl, alkenoxyC0-6alkyl, alkynoxyC0-6alkyl, C1-6alkoxyC0-6alkyl, C1-6alkylthioC0-6alkyl, C2-6alkenyl, acylC2-6alkenyl, C2-6alkynyl, acylC2-6alkynyl, arC0-6alkylaminoC0-6alkyl, arC0-6alkylthioC0-6alkyl, arC0-6alkoxyC0-6alkyl, substituted arC0-6alkoxy, substituted arC0-6alkylthio, or substituted arC0-6alkoxy;
- R4, R41, and R42 each independently is C0-6alkyl, cycloC3-10alkyl, oxo, halogen, haloalkyl, cyanoC0-6alkyl, nitroC0-6alkyl, hydroxyC0-6alkyl, (C0-6alkyl)(C0-6alkyl)aminoC0-6alkyl, (C0-6alkyl)(C0-6alkyl)amino(C1-6alkyl)(C0-6alkyl)amino, acylaminoC0-6alkylamino, acylC0-6alkyl, substituted acyl, guanidinoC0-6alkyl, hydroxyiminoC0-6alkyl, acylaminoC0-6alkyl, substituted acylamino, acyloxyC0-6alkyl, substituted acyloxy, arC0-6alkyl, substituted arC0-6alkyl, heteroarylC0-6alkyl, substituted heteroarylC0-6alkyl, heterocyclylC0-6alkyl, cyanoaminoC0-6alkyl, C0-6alkylhydrazino, heterocyclylamino, arC0-6alkylhydrazino, alkylsulfonylC0-6alkyl, arC0-6alkylsulfonylC0-6alkyl, alkylsulfinylC0-6alkyl, alkylsulfonamidoC0-6alkyl, arC0-6alkylsulfonamidoC0-6alkyl, aminoC0-6alkylsulfonyl, C0-6alkylaminosulfonyl, acylC1-6alkylsulfonyl, heterocyclylsulfonyl, aminoC0-6alkylsulfinyl, acylC1-6alkylsulfinyl, silyl, siloxy, alkenoxy, alkynoxy, C2-6alkenyl, acylC2-6alkenyl, C2-6alkynyl, acylC2-6alkynyl, hydroxyC2-6alkynyl, aminoC2-6alkynyl, C1-6alkoxyC0-6alkyl, C1-6alkylthioC0-6alkyl, hydroxyC1-6alkoxyC0-6alkyl, hydroxyC1-6alkylthioC0-6alkyl, acylC1-6alkoxyC0-6alkyl, acylC1-6alkylthioC0-6alkyl, C0-6alkylaminoC1-6alkoxyC0-6alkyl, C0-6alkylaminoC1-6alkylthioC0-6alkyl, acylaminoC1-6alkoxyC0-6alkyl, acylaminoC1-6alkylthioC0-6alkyl, arC0-6alkylaminoC0-6alkyl, arC0-6alkylthioC0-6alkyl, arC0-6alkoxyC0-6alkyl, arC0-6alkylamino, arC0-6alkylaminoC0-6alkyl, arC0-6alkylthio, substituted arC0-6alkoxy, substituted arC0-6alkylthio, or substituted arC0-6alkoxy;
- and
- R5 is C0-6alkyl, C1-6alkoxyC1-6alkyl, C1-6alkylthioC1-6alkyl, C0-6alkylaminoC1-6alkyl, arC0-6alkyl, or
- R5 is a bridge between the N atom to which it is attached and one of the C ring atoms of Y, forming a bicyclic heteroaryl group.
9 more elements
A compound consisting of
- N-(3-{[1-(dimethylamino)-2-nitrovinyl]amino}phenyl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
- N-(4-{[1-[(2-morpholin-4-yl-ethyl)amino]-2-nitrovinyl]amino}phenyl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
- N-(4-{[1-[(2-piperidin-1-yl-ethyl)amino]-2-nitrovinyl]amino}phenyl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
- N-(3-{[1-[(2-methoxyethyl)amino]-2-nitrovinyl]amino}phenyl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
- N-(4-{[1-[(pyridin-3-yl-methyl)amino]-2-nitrovinyl]amino}phenyl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
- N-(4-{[1-amino-2-nitrovinyl]amino}phenyl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
- N-(3-{[1-amino-2-nitrovinyl]amino}phenyl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
- N-(3-{[1-[(pyridin-3-yl-methyl)amino]-2-nitrovinyl]amino}phenyl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
- N-(3-{[1-[(2-(dimethylamino)ethyl)amino]-2-nitrovinyl]amino}phenyl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
- N-(4-{[1-methylamino-2-nitrovinyl]amino}phenyl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
- N-(4-{[1-[(2-methoxyethyl)amino]-2-nitrovinyl]amino}phenyl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
- N-(3-{[1-[(2-piperidin-1-yl-ethyl)amino]-2-nitrovinyl]amino}phenyl)-3-[(quinolin-4-ylmethyl)amino]thiophene-2-carboxamide;
- or a pharmaceutically acceptable salt, or N-oxide, thereof.
10 more elements
Dependencies are inferred from the claim text.